Aberrant JAK/STAT signaling has been identified as a strong oncogenic factor involved in tumor growth, invasion, and metastasis [31, 35–43]; thus, potent JAK2 and STAT3 inhibitors have been developed [44–46] and are currently in different stages of preclinical and clinical investigations. This evidence concerns the gene JAK2 and neoplasm.